Arcturus Therapeutics Holdings financials
$13.70−5.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $82.0M | $152.3M | $166.8M | $206.0M | $12.4M | $9.5M | $20.8M |
| Gross profit | $82.0M | $152.3M | $166.8M | $206.0M | $12.4M | $9.5M | $20.8M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$76.3M | -$95.7M | -$78.2M | $12.2M | -$202.9M | -$71.5M | -$25.5M |
| Net income | -$65.8M | -$80.9M | -$29.7M | $9.3M | -$203.7M | -$72.1M | -$26.0M |
| Net margin | −80.2% | −53.1% | −17.8% | 4.5% | −1648.0% | −756.3% | −125.0% |
| Diluted EPS | $-2.40 | $-3.00 | $-1.12 | $0.35 | $-7.74 | $-3.55 | $-2.15 |
| EBITDA | -$73.2M | -$92.1M | -$75.2M | $13.7M | -$201.7M | -$70.6M | -$24.8M |
| Operating cash flow | -$74.3M | -$59.7M | -$18.1M | $32.0M | -$135.0M | -$42.9M | -$6.4M |
| Free cash flow | -$74.5M | -$60.4M | -$21.0M | $24.3M | -$138.4M | -$44.6M | -$7.3M |
| Diluted shares | 27.4M | 27.0M | 26.6M | 27.1M | 26.3M | 20.3M | 12.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $230.9M | $237.0M | $292.0M | $391.9M | $370.5M | $462.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $60.7M | $63.1M | $15.1M |
| Total assets | $271.1M | $344.1M | $429.4M | $450.4M | $392.8M | $476.5M |
| Total liabilities | $57.2M | $103.1M | $150.9M | $180.1M | $164.6M | $79.9M |
| Shareholders' equity | $214.0M | $241.0M | $278.5M | $270.3M | $228.2M | $396.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology